Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...
Patent
1988-07-28
1997-03-25
Feisee, Lila
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Blood proteins or globulins, e.g., proteoglycans, platelet...
53038825, C07K 1642
Patent
active
056146108
ABSTRACT:
The present invention relates to methods which utilize anti-idiotypic antibodies, or fragments thereof, for tumor immunotherapy or immunoprophylaxis. Monoclonal anti-idiotypic antibodies which recognize an idiotype present on a second antibody or on a T lymphocyte or on an immune suppressor factor which is directed against a defined tumor antigen, can be used for immunization against a tumor, for immune anti-tumor activation or inhibition of suppression, or for in vitro activation of lymphocytes to be used in adoptive immunotherapy. The anti-idiotypic antibodies, or fragments thereof, can also be used to monitor anti-antibody induction in patients undergoing passive immunization to a tumor antigen by administration of anti-tumor antibody. In another embodiment, administration of T lymphocytes which express an idiotype directed against a defined tumor antigen can be used to transfer delayed-type hypersensitivity to the tumor. In another method of the invention, the induction of anti-idiotypic antibodies in vivo by administration of anti-tumor antibody or immune cells or factors exhibiting an anti-tumor idiotype can be therapeutically valuable.
REFERENCES:
patent: 4699880 (1987-10-01), Goldstein
patent: 4906562 (1990-03-01), Hellstrom et al.
patent: 4918164 (1990-04-01), Hellstrom et al.
Jerne, N. K., 1974 "Towards a Network Theory of the Immune System," Ann. Immunol. (Paris) 125c:373-389.
Jerne et al., 1982, "Recurrent Idiotopes and Internal Images," The EMBO Journal 1(2):243-247.
Nepom et al., 1984, "Induction of immunity to a human tumor marker by in vivo administration of anti-idiotypic antibodies in mice," Proc. Natl. Acad. Sci. U.S.A. 81:2864-2867.
Forstrom et al., 1983, "Immunization to a Syngeneic Sarcoma by a Monoclonal Auto-Anti-Idiotypic Antibody," Nature 303:627-629.
Flood et al., 1980, "Suppression of Tumor Rejection by Autologous Anti-Idiotypic Immunity," Proc. Natl. Acad. Sci. U.S.A. 77:2209-2213.
Binz et al., 1982, "Induction or Elimination of Tumor-Specific Immunity Against a Chemically-Induced Rat Tumor Using Auto-Anti-Idiotypic Immunity," Int. J. Cancer 29:417-423.
Tilkin et al., 1981, "Reduced Tumor Growth After Low-Dose Irradiation or Immunization Against Blastic Suppressor T Cells," Proc. Natl. Acad. Sci. U.S.A. 78:1809-1812.
Kennedy et al., 1985, "Suppression of In Vivo Tumor Formation Induced By Simian Virus 40-Transformed Cells in Mice Receiving Antiidiotypic Antibodies," J. Exp. Med. 161:1432-1449.
Koprowski et al., 1984, "Human Anti-Idiotype Antibodies in Cancer Patients: Is the Modulation of the Immune Response Beneficial for the Patient?" Proc. Natl. Acad. Sci. U.S.A. 81:216-219.
Brown et al., 1981, "Structural Characterization of Human Melanoma-Associated Antigen p97 with Monoclonal Antibodies," J. Immunol. 127:539-546.
Hellstrom et al., 1986, "Monoclonal Mouse Antibodies Raised against Human Lung Carcinoma," Cancer Res. 46:3917-3923.
Hellstrom et al., 1986, "Antitumor Effects of L6, and IgG2a Antibody That Reacts with Most Human Carcinomas," Proc. Natl. Acad. Sci. U.S.A. 83:7059-7063.
Perosa and Ferrone, 1987, "Syngeneic Anti-Idiotypic Antisera to Murine Anti-HLA Class II Monoclonal Antibodies," J. Immunol. 139:1232-1239.
Tsujisaki et al., 1986, "A sandwich assay to detect and characterize syngeneic anti-idiotypic antibodies to murine anti-HLA and tumor associated antigen monoclonal antibodies," J. of Immunological Methods 95:47-55.
Beaton Donna F.
Hellstrom Ingegerd
Hellstrom Karl E.
Kahn Maria S.
Feisee Lila
Oncogen
LandOfFree
Tumor immunotherapy using anti-idiotypic antibodies does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Tumor immunotherapy using anti-idiotypic antibodies, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Tumor immunotherapy using anti-idiotypic antibodies will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2204400